Mr. Thomas Smeenk reports

HEMOSTEMIX ANNOUNCES THE INCORPORATION OF HEMOSTEMIX QUEBEC INC. AND $6 MILLION IN GRANT APPLICATIONS

Hemostemix Inc. has incorporated Hemostemix Quebec Inc. and has applied for grant financing of $6-million to locate production of ACP-01 in Montreal.

"We are moving production of ACP-01 to Quebec, as have negotiated terms for a possible shared site where we can co-locate our staff to produce a treatment for clinical trials at one-tenth the cost of contract manufacturers," stated Thomas Smeenk, chief executive officer. "We also have drafted a phase II heart (ischemic cardiomyopathy) clinical trial protocol, which will be submitted to regulators shortly. With the grants, we will build out production, and our patented automated cell therapy system (ACTS), to generate revenue from the sale of ACP-01 as an exemption approved compassionate treatment for critical limb ischemia, while completing phase II-III clinical trials," Mr. Smeenk said.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy company, founded in 2003.

We seek Safe Harbor.